Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystalline form of tiotropium bromide

A kind of technology of tiotropium bromide and crystallization, applied in the field of crystalline form of tiotropium bromide, can solve the problems such as not describing single use of NMP, not mentioning obtaining crystalline form

Inactive Publication Date: 2014-10-15
CERBIOS PHARMA
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of NMP alone is not described in this previous application, and no mention is made of obtaining new crystalline forms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline form of tiotropium bromide
  • Crystalline form of tiotropium bromide
  • Crystalline form of tiotropium bromide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Preparation of desmethyltiotropium bromide (4) in NMP from scopolamine (3) free base

[0042] A mixture of 4.0 g (25.8 mmol) scopolamine (3) and 3.0 g (21.7 mmol, 0.84 equiv) of anhydrous potassium carbonate in 12 ml NMP was stirred at room temperature for 1 hour. After heating to 60°C, 6.56 g (25.8 mmol, 1.00 equivalent) of methyl di-(2-thienyl) glycolate (2) in 8 ml of NMP was added to the mixture, followed by 1.7 g (12.3 mmol , 0.48 equivalent) of anhydrous potassium carbonate. The temperature was raised to 70 °C and the reaction vessel was connected to vacuum (20 mbar) for 19 hours. TLC (ethyl acetate) indicated complete conversion of glycolate. After cooling to 0°C, 32 ml of 9% HCl was slowly added until pH~3. The dense precipitate was diluted with 20 mL of water and washed twice with 10 mL of toluene. The aqueous layer was cooled to 0°C and basified with 4.0 g potassium carbonate until pH~9. After 1 hour, the precipitate was filtered and washed with water unti...

Embodiment 2

[0047] Preparation of desmethyl-tiotropium bromide from scopolamine hydrochloride (4)

[0048]To a suspension of 100 g (0.522 mol) of scopolamine hydrochloride in 350 ml of DMF was added 72 g (0.521 mol, 1.0 equivalent) of anhydrous potassium carbonate. After gas evolution was complete, a solution of 159 g (0.625 mol, 1.2 eq) of methyl di-(2-thienyl)glycolate (2) in 300 mL of DMF was added. The reaction mixture was heated to 70 °C and vacuum (40 mbar) was applied. After one day, the mixture was ice-cooled and the pH was lowered to 3 with 9% hydrochloric acid, keeping the temperature below 25°C. The mixture was washed twice with 400 mL of toluene. The aqueous layer was basified with potassium carbonate and the resulting precipitate was collected by filtration and washed with water until neutral pH. The crude product was purified by crystallization from acetonitrile to afford 142 g (72%) of product as light brown crystals. Purity (HPLC): 99.8%.

[0049] 1 H-NMR (300MHz,d ...

Embodiment 3

[0052] Preparation of Tiotropium Bromide in NMP (1)

[0053] To a solution of 13.2 g (39.1 mmol) of desmethyltiotropium (4) in 30 mL of NMP was added 16.5 mL (115 mmol, 2.93 eq) of methyl bromide in NMP 1:1 (W / W) solution. The mixture was stirred overnight at room temperature whereupon a dense suspension formed. After adding 20 mL of acetonitrile, the suspension was filtered, washed with 20 mL of acetonitrile, and dried overnight at 30° C. under high vacuum to yield 15.51 g of an off-white powder. Residual solvents were detected by GC analysis. XRPD spectrum with figure 1 The spectra shown are consistent.

[0054] 1 H-NMR (300MHz,d 6 -DMSO):7.52(dd,J=5.0Hz,1.1,2H),7.41(s,1H),7.13(dd,J=3.6,1.1Hz,2H),7.01(dd,J=5.0,3.7Hz, 2H),5.12(t,J=5.8Hz,1H),4.13(bd,J=5.8Hz,2H),3.50(s,2H),3.25(s,3H),3.05(s,3H),2.8- 2.6(m,2H),1.93(s,1H),1.87(s,1H).

[0055] 13 C-NMR (75.5MHz,d 6 -DMSO): 170.2, 147.1, 127.3, 126.7, 126.3, 76.8, 65.0, 64.2, 56.5, 54.1, 47.6, 28.7.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A stable crystalline form of tiotropium bromide, and a process for its preparation with high purity are provided.

Description

[0001] describe [0002] The present invention relates to a stable crystalline form of tiotropium bromide and a process for preparing said stable crystalline form of tiotropium bromide with high purity. Background of the invention [0003] 1α,2β,4β,7β)-7-[(Hydroxy-di-2-thiopheneacetyl)oxy]-9,9-dimethyl-3-oxa-9-azonium tricyclo[3.3.1.0 2,4 ] nonane bromide, known as tiotropium bromide (1) [0004] [0005] Is a very potent anticholinergic drug with specificity for muscarinic receptors and broad long-term effects. As a bronchodilator, it offers a therapeutic advantage in the treatment of chronic obstructive pulmonary disease (COPD) or asthma. [0006] The drug ingredient is used in low therapeutic doses of 18-20 micrograms and is preferably administered by inhalation and is available as Commercially available. [0007] A method for the preparation of tiotropium bromide (1) was first reported in EP0418716 by reacting the corresponding cyclic tertiary amine dissolved in di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D451/10
CPCC07D451/10C07D491/18A61P11/06
Inventor A·莫鲁M·莫罗索利U·彭内M·佩瑟戈希尼
Owner CERBIOS PHARMA